Clinical outcomes and prognostic factors in triple-negative invasive lobular carcinoma of the breast

Utsav Joshi, Pravash Budhathoki, Suman Gaire, Sumeet K. Yadav, Anish Shah, Anurag Adhikari, Grace Choong, Rima Couzi, Karthik V. Giridhar, Roberto A. Leon-Ferre, Judy C. Boughey, Tina J. Hieken, Robert Mutter, Kathryn J. Ruddy, Tufia C. Haddad, Matthew P. Goetz, Fergus J. Couch, Siddhartha Yadav

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: Triple-negative invasive lobular carcinoma (TN-ILC) of breast cancer is a rare disease and the clinical outcomes and prognostic factors are not well-defined. Methods: Women with stage I–III TN-ILC or triple-negative invasive ductal carcinoma (TN-IDC) of the breast undergoing mastectomy or breast-conserving surgery between 2010 and 2018 in the National Cancer Database were included. Kaplan–Meier curves and multivariate Cox proportional hazard regression were used to compare overall survival (OS) and evaluate prognostic factors. Multivariate logistic regression was performed to analyze the factors associated with pathological response to neoadjuvant chemotherapy. Results: The median age at diagnosis for women with TN-ILC was 67 years compared to 58 years in TN-IDC (p < 0.001). There was no significant difference in the OS between TN-ILC and TN-IDC in multivariate analysis (HR 0.96, p = 0.44). Black race and higher TNM stage were associated with worse OS, whereas receipt of chemotherapy or radiation was associated with better OS in TN-ILC. Among women with TN-ILC receiving neoadjuvant chemotherapy, the 5-year OS was 77.3% in women with a complete pathological response (pCR) compared to 39.8% in women without any response. The odds of achieving pCR following neoadjuvant chemotherapy were significantly lower in women with TN-ILC compared to TN-IDC (OR 0.53, p < 0.001). Conclusion: Women with TN-ILC are older at diagnosis but have similar OS compared to TN-IDC after adjusting for tumor and demographic characteristics. Administration of chemotherapy was associated with improved OS in TN-ILC, but women with TN-ILC were less likely to achieve complete response to neoadjuvant therapy compared to TN-IDC.

Original languageEnglish (US)
Pages (from-to)217-224
Number of pages8
JournalBreast Cancer Research and Treatment
Volume200
Issue number2
DOIs
StatePublished - Jul 2023

Keywords

  • Chemotherapy
  • Lobular breast cancer
  • Neoadjuvant
  • Survival
  • Triple negative

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Clinical outcomes and prognostic factors in triple-negative invasive lobular carcinoma of the breast'. Together they form a unique fingerprint.

Cite this